Trastuzumab as the laed monoclonal antibody in advanced breast cancer: Choosing which patient and when

Future Oncology

Volumn 4, Issue 1, 2008, Pages 125-131

  Olver, Ian N ^a  

^a The Cancer Council Australia   (Australia)

Author keywords

Bevacizumab; Breast cancer; Cardiotoxicity; HER2; Lapatinib; Metastatic; Monclonal antibody; Pertuzumab; Taxanes; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HORMONE; LAPATINIB; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; VINFLUNINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADD ON THERAPY; ADVANCED CANCER; ANEMIA; BRAIN METASTASIS; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CHOICE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; HEART DISEASE; HER2 POSITIVE BREAST CANCER; HUMAN; INFECTION; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NEUTROPENIA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG TOXICITY; FEMALE; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG TOXICITY; FEMALE; HUMANS; PATIENT SELECTION; RECEPTOR, ERBB-2;

EID: 39549084113     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.1.125     Document Type: Review

References (45)

1. Mass RD, Press MF, Anderson S et al.: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin. Breast Cancer 6, 240-246 (2005).
2. Tubbs RR, Hicks DG, Cook J et al.: Fluorescence in situ Hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarrinoma of the breast: a single institution experience. Diagn. Mol. Pathol. 16(4), 207-10 (2007).
3. Wolff AC, Hammond MEH, Schwartz JN et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25(1), 118-145 (2007).
4. Cobleigh MA, Vogel CL, Tripathy D et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648(1999).
5. Harris K, Washington C, Lieberman JF et al.: A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications of clinical dosing. Proc. Am. Soc. Clin. Oncol. 21, 123 (2002) (Abstract 488).
6. Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2002).
7. Osoba D, Slamon DJ, Burchmore M, Murphy M: Effects of quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J. Clin. Oncol. 20(14), 3106-3113 (2002).
8. Marty M, Cognetti F, Maraninchi D et al.: Randomized Phase II trial of the efficacy, and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first line treatment: The M77001 Study Group. J. Clin. Oncol. 23, 4265-4274 (2005).
9. Robert N, Leyland-Jones B, Asmar L et al.: Randomized Phase II study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol. 24(18), 2786-2792 (2006).
10. Pegram M, Forbes J, Pienkowski T et al.: BCIRG 007: first overall survival analysis of randomised Phase II trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 1008).
11. Perez EA, Suman VJ, Rowland KM et al.: Two concurrent Phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing mewtatic breast cancer. NCTG study 983252. Clin. Breast Cancer 6(5), 425-432 (2005).
12. Burstein HJ, Keshaviah A, Baron AD et al.: Trastuzumab plus taxane chemotherapy for HER2-overexpressing metastatic breast cancer. the trastuzumab asid vinorelbine or taxane study. Cancer 110, 965-972 (2007).
13. Bartsch R. Wenzel C, Altorjai G et al.: Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J. Clin. Oncol. 25(25), 3853-3858 (2007).
14. O'Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE: Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin. Breast Cancer 5(2), 142-147 (2004).
15. Paridaens R, Wildiers H, Dalenc F et al.: Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 1058).
16. Neskovic-Konstantinovic Z, Nooji M, Khaled H et al.: Safety and efficacy of combined trastuzumab and CMF therapy in women with metastatic breast cancer EORTC protocol 10995. J. Clin. Oncol. 25(18S), (2007) (Abstract 1040).
17. Morabito A, Longo R, Gattuso D et al.: Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol. Rep. 16(2), 393-398 (2006).
18. Chan A, Ganju V, Becquart D et al.: Efficacy of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination (NVBoXH) in HER2-positive metastatic breast cancer (MBC: first results of an international Phase II trial. J. Clin. Oncol. 25(18S), Abstract 1053 (2007).
19. Baselga J, Semigalzov V, Manikhas GM et al.: Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial. Eur. J. Cancer Suppl. 4(5), (2007) (Abstract 2030).
20. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P: Isolated central nervous system metastases in patients with HERZ2-overexpressing advanced breast cancer treated with first line trastuzumab-based therapy. Ann. Oncol. 16, 1772-1777 (2095).
21. Pinder MC, Chang H, Broglio KR et al.: Trastuzumab treatment and the risk of central nervous system (CNS) metastases, J. Clin. Oncol. 25(18S), (2007) (Abstract 1018).
22. Lin NU, Winer EP: Brain metastases: The HER2 paradigm. Clin. Cancer Res. 13, 1648-1655 (2007).
23. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer 7(8), 600-606 (2007).
24. De Tursi M, Carella C, Ricevuto A et al.: A multicenter Phase II study of epirubicin with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC). J. Clin. Oncol. 25(18S), (2007) (Abstract 1060).
25. Chia S, Clemons M, Martin LA et al.: Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter Phase II trial. J. Clin. Oncol. 24(18), 2773-2778(2006).
26. Fountzilas G, Razis E, Tsavdaridis D et al.: Continuation of trastuzumab beyond disease progression is feasible and safe in, patients with metastatic breast cancer: a retrospective analysis of 8O cases by the hellenic cooperative oncology group. Clin. Breast Cancer 4(2), 120-125 (2003).
27. Gelmoh KA, Mackey J, Verma S et al.: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin, Breast Cancer 5(1), 52-58 (2004).
28. Metro G, Mottolese M, Di Cosimo S et al.: Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC). J. Clin. Oncol. 25(18S), (2007) (Abstract 1066).
29. Tripathy D, Slamon DJ, Cobleigh M et al.: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 22(6), 1063-1070 (2004).
30. Bachelor T, Mauriac L, Delcambre C et al.: Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER-positive metastatic breast cancer beyond disease progression. J. Clin. Oncol. 25(18S) (2007) (Abstract 1094).
31. Mackey JR, Kaufman B, Clemens M et al.: Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. 100(Suppl. 1), (2006) (Abstract 3a).
32. Brockhoff G, Heckel B, Schmidt-Bruecken E et al.: Differential impact of cetuximab, pertuzumab and trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 40(4), 488-507 (2007).
33. Portera CC, Walshe JM, Denduluri N et al.: A report of cardiac events in a Phase II clinical study using trastuzumab combined with pertuzumab in HER2-positive metastatic breast cancer (MBC). J Clin. Oncol. 25(18S), (2007) (Abstract 1028).
34. Miller KD: E2 100: a Phase III trial of paclitaxel versus paclitaxel/ bevacizumab for metastatic breast cancer. Clin. Breast Cancer 3(6),421-422 (2003).
35. Pegram M, Chan D, Dichman RA et al.: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res Treat. 100(Suppl. 1), (2006) (Abstract 310a).
36. Gomez HL, Chavez MA, Doval DC et al.: A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 3046).
37. Lin NU, Dieras V, Paul D et al.: EGF105084, a Phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J. Clin. Oncol. 25(18S), (2007) (Abstract 1012).
38. Geyer CE, Forster J, Lindquist D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
39. Konecny GE, Pegram, MD, Venkatesan N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpresssing and trastuzumab treated breast cancer cells. Cancer Res 66, 1630-1639 (2006).
40. Storniolo A, Burris H, Pegram M et al.: A Phase I open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. J. Clin. Oncol. 23 (Suppl. 16), (2005) (Abstrack 559).
41. Beeram M, Krop I, Modi S et al.: A Phase I study of trastuzumab-MCC-DM1 (TDM1), a firs-in-class HER2 antibody-drug conjugate (ADC), inpatients (pts) with HER2+ metastatic breast cancer (BC). J. Clin. Oncol. 25(18S), (2007) (Abstract 1042).
42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2 positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
43. Romond EH, Perez EA Bryant J et al.: Trastuzumab plus adjuvant therapy for operable HER2 positive breast cancer. N. Engl. J. Med 353, 1673-1684 (2005).
44. Perez AE, Romond EH, Suman VJ et al.: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J. Clin. Oncol. 25(18S), (2007) (Abstract 512).
45. Joensuu H, Kellokumpu-lehtinen. PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).